Information Provided By: 
Fly News Breaks for July 9, 2019
MYGN
Jul 9, 2019 | 07:18 EDT
Cowen analyst Doug Schenkel downgraded Myriad Genetics to Market Perform from Outperform and lowered his price target for the shares to $30 from $37, citing a combination of lower overall conviction in Myriad and a less attractive relative valuation. In a research note to investors, Schenkel says that while many key pillars to his January 2019 upgrade remain "somewhat intact," Myriad's year-to-date execution has not been completely spotless and there have been some negative developments.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
